Evaluation of the ACO – Executive Summary now up on the ACO website

Published on March 14, 2016 in Buzz, News, Reports & Articles

The Canadian HIV Vaccine Initiative (CHVI) was established in 2007 as Canada’s contribution to the development of a safe, effective, and affordable HIV vaccine, accessible on a global scale. In 2011, the CHVI Research and Development Alliance Coordinating Office (ACO) was formed as a neutral organization aimed at facilitating collaboration, igniting synergies across disciplines, sectors, and geographic boundaries, capitalizing on Canada’s strengths, and ensuring that Canada is a leader in the HIV vaccine research effort.

In the past year, Cathexis conducted an evaluation of the ACO. The executive summary can be found here.